The SSRP Institute announced that Medivive has joined its Trusted Partner Network following nomination and internal vetting aligned with SSRP’s mission of advancing science-first, education-driven clinical collaboration.

Medivive offers an advanced approach to NAD⁺ therapy designed to support cellular energetics through sterile, clinician-prescribed formulations produced under current Good Manufacturing Practices (cGMP) and dispensed by licensed pharmacies. Delivered subcutaneously, Medivive’s NAD⁺ therapy is designed to improve bioavailability compared to oral precursors while supporting tissue energy production and redox balance under medical supervision.

Jay Palmer, CEO and Co-Founder of Medivive, says, “Dr Seeds and I have known each other for a while, and when we started talking about what Medivive was building, the fit was obvious. SSRP practitioners hold their protocols to a high standard, and the Medivive pen was built to match it. This is the first prefilled NAD+ subcutaneous injector pen manufactured to cGMP standards at a 503B outsourcing facility in the US. Drug-grade testing on every batch, delivered the right way, with zero burden on the practice. We are proud to be the preferred NAD+ provider for this community.”

"Now, we can feel more confident in measuring and following the evidence on this with a safe product,” Dr William Seeds, Founder and Academic Chairman of the SSRP Institute, said recently on Episode 50 of his podcast, Redox Revolution. “This really opens the door to some powerful things you can start doing as you work to help that patient. I mean, it's things that I have not been able to do for a very long time.”

Certificates of Analysis covering potency, sterility, and endotoxin testing are maintained for every batch and are available to prescribers upon request. Medivive’s dedicated Partner Page is now live and provides SSRP Members with information about their offerings, research background, and ways they support clinical practice.